2026 年至 2032 年深層靜脈栓塞症市場（依藥物類別、治療方法、通路、最終用戶和地區分類）

深層靜脈栓塞症（DVT）全球市場評估 - 2026-2032

由於久坐的生活方式、肥胖、老齡以及吸煙和糖尿病等危險因素的存在，全球深層靜脈栓塞症(DVT) 的盛行率正在上升。盛行率的上升使得對有效 DVT 治療方案的需求日益成長。早期診斷和及時治療對於預防併發症和最佳化患者預後至關重要，從而導致對 DVT 治療方案的需求增加，預計 2024 年將超過 11.1 億美元，到 2032 年將達到約 14.8 億美元。

除此之外，我們也非常重視開發創新和改進的 DVT治療方法。隨著公司投資研發，為患者提供療效、安全性和便利性更高的新藥、醫療設備和治療方法，該利基市場預計在 2026 年至 2032 年期間以 3.96% 的複合年成長率成長。

深層靜脈栓塞症（DVT）全球市場定義/概述

深層靜脈栓塞症(DVT) 是一種以深部靜脈栓塞為特徵的疾病，通常位於腿部。這些血塊會阻塞血流並增加肺動脈栓塞的風險，這是一種危及生命的併發症。

深部靜脈血栓 (DVT) 的治療重點是防止血栓生長或破裂，並降低併發症的風險。治療方法包括抗凝血劑、血栓溶解藥物和機械血栓切除術。

持續的研究和開發正在推動 DVT 治療的進步。新型抗凝血藥物和微創手術不斷湧現，為患者提供更有效、更便利的治療方法。此外，早期診斷和預防策略的進步可能有助於改善患者的治療效果並降低 DVT 的發生率。

老年族群中深層靜脈栓塞症(DVT) 盛行率的不斷上升推動了 DVT 市場的成長嗎？

美國疾病管制與預防中心 (CDC) 報告稱，到 2023 年，65 歲及以上成年人因 DVT 住院的人數將增加 28%。診斷工具的技術進步，特別是攜帶式超音波設備，提高了早期檢測率。例如，2024 年 2 月，Medtronic宣布推出新的人工智慧 DVT 風險評估平台，早期檢測率提高了 40%。人們對 COVID 後患者 DVT 風險因素的認知提高也促進了這一發展，美國國立衛生研究院報告稱，2023 年，31% 的嚴重 COVID-19 患者出現了 DVT併發症。

受全球醫療保健支出增加的推動，新型抗凝血療法和機械預防設備的採用日益增多，推動了市場的成長。根據醫療保險和醫療補助服務中心的數據，預計 2023 年 DVT 預防和治療支出將達到 123 億美元，年成長率為 7.2%。例如，2024年3月，強生公司的子公司Ethicon透露，其新型機械壓迫裝置的臨床測試使術後DVT發生率降低了45%。微創手術的興起和醫院強制性的 DVT 風險評估通訊協定進一步推動了市場擴張。

全球深層靜脈栓塞症(DVT) 市場面臨哪些挑戰，包括市場進入和治療成本上升？

高昂的治療費用和有限的報銷政策對 DVT 市場構成了重大挑戰，美國醫療保健研究與品質機構報告稱，到 2023 年，每例 DVT 患者的平均住院費用將達到 14,800 美元。在保險覆蓋先進治療手段稀缺的發展中地區，經濟負擔尤其沉重。例如，2024 年 3 月，百時美施貴寶宣布，儘管其新型抗凝血療法的臨床結果良好，但 22% 的聯合療法患者仍被保險拒絕。患者堅持長期抗凝血治療仍有問題，治療開始後的前 6 個月內停藥率高達 30%。

DVT 市場面臨在不同醫療環境中標準化診斷方案和治療方法的挑戰，世界衛生組織報告稱，到 2023 年，不同地區的 DVT 管理將出現顯著差異。基層醫療醫生對 DVT 早期症狀和風險因素的認知不足，導致及時干預和最佳患者治療結果的延遲。

目錄

第1章全球深層靜脈栓塞症市場簡介

• 市場概覽
• 研究範圍
• 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

• 資料探勘
• 驗證
• 第一手資料
• 資料來源列表

第4章全球深層靜脈栓塞症市場展望

• 概述
• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 波特五力模型
• 價值鏈分析

第5章 全球深層靜脈栓塞症市場（依治療方法）

• 概述
• 血栓溶解劑
• 血液稀釋劑
• 下腔靜脈濾器
• 壓力襪

第6章全球深層靜脈栓塞症市場按分銷管道

• 概述
• 零售藥局
• 醫院藥房
• 電子商務

第7章全球深層靜脈栓塞症市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 其他
  • 拉丁美洲
  • 中東和非洲

8. 全球深層靜脈栓塞症市場的競爭格局

• 概述
• 各公司市場排名
• 重點發展策略

第9章 公司簡介

• Abbott Laboratories
• Bristol-Myers
• Squibb Company
• Pfizer
• Sanofi-Aventis
• Daiichi Sankyo Co. Ltd.
• Johnson & Johnson
• GSK
• Bayer
• Astellas Pharma

第10章 附錄

• 相關調查

Global Deep Vein Thrombosis (DVT) Market Valuation - 2026-2032

The global prevalence of deep vein thrombosis (DVT) is rising, driven by factors such as sedentary lifestyles, obesity, geriatric populations, and the presence of risk factors like smoking and diabetes. This increasing incidence has led to a growing demand for effective DVT treatment options. Early diagnosis and prompt treatment are crucial for preventing complications and optimizing patient outcomes, consequently driving the demand for DVT treatment options, surpassing USD 1.11 Billion valued in 2024 to reach a valuation of around USD 1.48 Billion by 2032.

In addition to this, ongoing efforts are focused on developing innovative and improved treatments for DVT. Companies are investing in research and development to introduce novel drugs, medical devices, and therapies that offer enhanced efficacy, safety, and convenience for patients, thus enabling the niche market grow at a CAGR of 3.96% from 2026 to 2032.

Global Deep Vein Thrombosis (DVT) Market: Definition/ Overview

Deep vein thrombosis (DVT) is a medical condition characterized by the formation of a blood clot in a deep vein, typically located in the legs. This clot can obstruct blood flow and increase the risk of pulmonary embolism, a potentially life-threatening complication.

The treatment of DVT focuses on preventing the clot from growing and breaking off, as well as reducing the risk of complications. Treatment options may include anticoagulant medications, thrombolytics, and mechanical thrombectomy.

Ongoing research and development efforts are driving advancements in DVT treatment. New anticoagulant medications and minimally invasive procedures are being developed to provide more effective and convenient options for patients. Additionally, advancements in early diagnosis and prevention strategies will contribute to improved patient outcomes and reduced incidence of DVT.

How are the Rising Rising Prevalence of DVT Among Geriatric Populations Fueling the Growth of the Global Deep Vein Thrombosis (DVT) Market?

The rising prevalence of DVT, particularly among geriatric populations and post-surgical patients, is significantly expanding the market demand, with the CDC reporting a 28% increase in DVT-related hospitalizations among adults over 65 in 2023. Technological advancements in diagnostic tools, especially portable ultrasound devices, have improved early detection rates. For instance, in February 2024, Medtronic announced the launch of their new AI-powered DVT risk assessment platform, showing a 40% improvement in early detection rates. The growing awareness of DVT risk factors in post-COVID patients has also contributed to market growth, with the NIH reporting that 31% of severe COVID-19 patients developed DVT complications in 2023.

The expanding adoption of novel anticoagulant therapies and mechanical prophylaxis devices is driving market growth, supported by increasing healthcare expenditure globally. According to the Centers for Medicare & Medicaid Services, DVT prevention and treatment costs reached $12.3 billion in 2023, with a projected 7.2% annual increase. For instance, in March 2024, Johnson & Johnson's subsidiary Ethicon revealed that their new mechanical compression device achieved a 45% reduction in post-operative DVT incidents during clinical trials. The rise in minimally invasive surgical procedures and the increasing implementation of mandatory DVT risk assessment protocols in hospitals have further stimulated market expansion.

How are the Market Access and Rising Treatment Cost Hindering the Global Deep Vein Thrombosis (DVT) Market Growth?

High treatment costs and limited reimbursement policies pose significant challenges in the DVT market, with the Agency for Healthcare Research and Quality reporting an average hospitalization cost of $14,800 per DVT case in 2023. The financial burden is particularly challenging in developing regions, where insurance coverage for advanced treatments remains inadequate. For instance, in March 2024, Bristol Myers Squibb announced that despite positive clinical outcomes, insurance denials for their novel anticoagulant therapy affected 22% of prescribed patients. Patient adherence to long-term anticoagulation therapy remains problematic, with discontinuation rates reaching 30% within the first six months of treatment.

The DVT market faces challenges in standardizing diagnostic protocols and treatment approaches across different healthcare settings, with the WHO reporting significant variations in DVT management practices across regions in 2023. Limited awareness among primary care physicians about early DVT symptoms and risk factors continues to delay timely interventions and optimal patient outcomes.

Category-Wise Acumens

What are the Features Bolstering the Demand of Anticoagulants Segment?

The anticoagulants segment maintains its market dominance due to its proven efficacy and expanding therapeutic options, with the FDA reporting a 28% increase in anticoagulant prescriptions for DVT treatment in 2023 compared to the previous year. Direct oral anticoagulants (DOACs) have revolutionized DVT management by offering convenient dosing regimens and reduced monitoring requirements. The development of reversal agents for anticoagulants has enhanced their safety profile, making them the preferred choice among healthcare providers and patients alike.

The market growth is further propelled by the introduction of biosimilars and generic alternatives, making treatment more accessible and cost-effective, with the U.S. Department of Health reporting a 31% reduction in average treatment costs for DVT patients using generic anticoagulants in 2023. Recent advancements in drug delivery systems and personalized dosing approaches have improved patient compliance and treatment outcomes. The expansion of indication ranges for existing anticoagulants and increased insurance coverage have significantly contributed to market penetration across different patient populations.

What Factors are Responsible to Project the Market Growth of Surgical Segment?

The surgical segment is dominating the global deep vein thrombosis (DVT) market, driven by the increasing adoption of minimally invasive thrombectomy procedures, with the FDA reporting a 28% year-over-year increase in approved surgical devices for DVT in 2023. The segment's growth is further propelled by technological advancements in surgical techniques and equipment, particularly in mechanical thrombectomy devices. The rising prevalence of post-operative DVT cases, especially in orthopedic and bariatric surgeries, has created a substantial demand for surgical interventions.

Advanced surgical techniques have shown superior outcomes in treating extensive DVT cases, with the American College of Surgeons reporting a 32% reduction in post-thrombotic syndrome when surgical interventions are used as primary treatment in 2023. The integration of robotic-assisted surgical systems and image-guided procedures has improved precision and reduced recovery times, making surgical options more appealing to both healthcare providers and patients.

Country/Region-wise Acumens

How are the Advanced Healthcare Infrastructure and Market Players Maintaining the

North American Deep Vein Thrombosis (DVT) Dominance?

The North American DVT treatment market is maintaining its global dominance, largely driven by the United States, where according to the CDC's 2023 data, between 60,000-100,000 Americans die annually from DVT/PE (Pulmonary Embolism). This robust market position is further strengthened by the region's advanced healthcare infrastructure and the presence of key market players, exemplified by Janssen Pharmaceuticals' March 2024 announcement of expanding their XARELTO(R) (rivaroxaban) manufacturing facility in Puerto Rico to meet growing demand.

The market's leadership is also attributed to high disease awareness and extensive insurance coverage, with Medicare reporting in December 2023 that DVT treatments, including newer direct oral anticoagulants (DOACs), are covered under Part D for over 65 million beneficiaries. This regional dominance was further solidified when Bristol Myers Squibb announced in January 2024 their collaboration with major U.S. healthcare systems to implement AI-driven DVT risk assessment protocols, potentially revolutionizing early detection and treatment approaches.

How are the Expanding Access to DVT Treatments Fueling the Demand of Deep Vein Thrombosis (DVT) in Asia Pacific?

The Asia Pacific region is experiencing significant growth in the global Deep Vein Thrombosis (DVT) treatment market. This growth is largely driven by rising incidences of DVT linked to sedentary lifestyles, obesity, and an geriatric population. Notably, government initiatives such as India's National Health Mission, which received about USD 5 million in funding for 2021-2022 to improve healthcare services, are enhancing access to DVT treatments.

Recent developments in the market further highlight this trend. For instance, in June 2021, the FDA approved Pradaxa (dabigatran etexilate) for pediatric patients aged 3 months to 12 years, marking a significant advancement in DVT treatment options. Additionally, major pharmaceutical companies like Pfizer and Bristol-Myers Squibb are increasing their investments in research and development, aiming to innovate and expand their product offerings in response to the growing demand for effective DVT therapies

Competitive Landscape

The global deep vein thrombosis (DVT) market is a dynamic and competitive landscape, with a mix of established players and emerging challengers vying for market share. These players are actively working to strengthen their presence by implementing strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are dedicated to continuously improving their product line to meet the needs of a wide range of customers in different regions.

Some of the key players operating in the global deep vein thrombosis (DVT) market include:

Aspen Holdings

Novartis AG

Mylan N.V.

Momenta Pharmaceuticals, Inc.

Hikma Pharmaceuticals PLC

Laboratorios FarmaceuticosRovi, S.A.

GL Pharma

Cobapharma

BoehringerIngelheim GmbH

Glenmark Pharmaceuticals Inc.

Latest Developments

In February 2024, for patients with deep vein thrombosis, Bayer initiated a Phase II clinical trial (SIRIUS study) for BAY3018250, a first-in-class anti-alpha2 antiplasmin (anti-a2ap) antibody. The plasmin inhibitor a2ap, which is essential for blood coagulation and breaks up clots in situ, is inhibited by BAY3018250.

In November 2023, during a Late-Breaking session of the American Heart Association (AHA) meeting, Anthos Therapeutics, Inc. reported a highly significant reduction in bleeding events across all primary and secondary endpoints by abelacimab when compared to a standard-of-care direct-oral anticoagulant (DOAC)

In June 2021, Pradaxa (dabigatran etexilate), the first oral blood thinner approved by the FDA, is used to treat DVT in children aged three months to twelve years.

Global Deep Vein Thrombosis (DVT) Market, By Category

• Drugs Class:
• Anticoagulants
• Heparin
• Others
• Treatment:
• Anticoagulants
• Heparin
• Others
• Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• End-User:
• Hospitals
• Homecare
• Specialty Clinics
• Others
• Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DEEP VEIN THROMBOSIS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DEEP VEIN THROMBOSIS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL DEEP VEIN THROMBOSIS MARKET, BY TREATMENT

• 5.1 Overview
• 5.2 Clot Busters
• 5.3 Blood Thinners
• 5.4 Inferior Vena Cava Filters
• 5.5 Compression Stocking

6 GLOBAL DEEP VEIN THROMBOSIS MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
• 6.2 Retail Pharmacy
• 6.3 Hospital Pharmacy
• 6.4 E-Commerce

7 GLOBAL DEEP VEIN THROMBOSIS MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL DEEP VEIN THROMBOSIS MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Abbott Laboratories
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Bristol-Myers
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Squibb Company
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Pfizer
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Sanofi-Aventis
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Daiichi Sankyo Co. Ltd.
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Johnson & Johnson
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 GSK
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Bayer
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Astellas Pharma
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research